\begin{table}[ht]
\centering
\resizebox{\textwidth}{!}{%

\begin{tabular}{|c|c|c|c|}
\hline
Drug name                & Clinical phase  & Mechanism of Action                                  & \begin{tabular}[c]{@{}c@{}}Number of \\ targeted proteins\end{tabular} \\ \hline
AI-10-49                 & Preclinical     & core binding factor inhibitor                        & 63                                                                     \\ \hline
Fenebrutinib             & Phase 2         & Bruton's tyrosine kinase (BTK) inhibitor             & 56                                                                     \\ \hline
PF-05190457              & Phase 2         & growth hormone secretagogue receptor inverse agonist & 42                                                                     \\ \hline
Abemaciclib              & Launched        & CDK inhibitor                                        & 21                                                                     \\ \hline
MK-5046                  & Preclinical     & bombesin receptor agonist                            & 18                                                                     \\ \hline
CFI-402257               & Phase 1/Phase 2 & dual specificity protein kinase inhibitor            & 14                                                                     \\ \hline
CCT137690                & Preclinical     & Aurora kinase inhibitor                              & 11                                                                     \\ \hline
Tropifexor               & Phase 2         & FXR agonist                                          & 5                                                                      \\ \hline
NMS-1286937              & Phase 2         & PLK inhibitor                                        & 5                                                                      \\ \hline
NMS-P715                 & Preclinical     & protein kinase inhibitor                             & 5                                                                      \\ \hline
Elbasvir                 & Launched        & HCV inhibitor                                        & 5                                                                      \\ \hline
Cilofexor                & Phase 3         & FXR agonist                                          & 4                                                                      \\ \hline
CDK9-IN-6                & Preclinical     & CDK inhibitor       
                                 & 3                                                                      \\ \hline
piperaquine-phosphate    & Launched        & antimalarial agent                                   & 3                                                                      \\ \hline
Q-203                    & Phase 2         & ATP synthase inhibitor                               & 3                                                                      \\ \hline
ABT 702 dihydrochloride  & Preclinical     & adenosine kinase inhibitor                           & 2                                                                      \\ \hline
Ziritaxestat             & Phase 3         & autotaxin inhibitor                                  & 2                                                                      \\ \hline
Adapalene                & Launched        & retinoid receptor agonist                            & 1                                                                      \\ \hline
Acalabrutinib            & Launched        & Bruton's tyrosine kinase (BTK) inhibitor             & 1                                                                      \\ \hline
IACS-10759 Hydrochloride & Preclinical     & mitochondrial complex I inhibitor                    & 1                                                                      \\ \hline
NVP-CGM097               & Phase 1         & MDM inhibitor                                        & 1                                                                      \\ \hline
\end{tabular}%
}
\caption{Chemicals interacted with undruggable human proteins} 
    \label{tab:chemicals}
\end{table}
Drug name Clinical phase Mechanism of Action Number of
targeted proteins
AI-10-49 Preclinical core binding factor inhibitor 63
Fenebrutinib Phase 2 Bruton’s tyrosine kinase (BTK) inhibitor 56
PF-05190457 Phase 2 growth hormone secretagogue receptor inverse agonist 42
Abemaciclib Launched CDK inhibitor 21
MK-5046 Preclinical bombesin receptor agonist 18
CFI-402257 Phase 1/Phase 2 dual specificity protein kinase inhibitor 14
CCT137690 Preclinical Aurora kinase inhibitor 11
Tropifexor Phase 2 FXR agonist 5
NMS-1286937 Phase 2 PLK inhibitor 5
NMS-P715 Preclinical protein kinase inhibitor 5
Elbasvir Launched HCV inhibitor 5
Cilofexor Phase 3 FXR agonist 4
CDK9-IN-6 Preclinical CDK inhibitor 3
piperaquine-phosphate Launched antimalarial agent 3
Q-203 Phase 2 ATP synthase inhibitor 3
ABT 702 dihydrochloride Preclinical adenosine kinase inhibitor 2
Ziritaxestat Phase 3 autotaxin inhibitor 2
Adapalene Launched retinoid receptor agonist 1
Acalabrutinib Launched Bruton’s tyrosine kinase (BTK) inhibitor 1
IACS-10759 Hydrochloride Preclinical mitochondrial complex I inhibitor 1
NVP-CGM097 Phase 1 MDM inhibitor 1